Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion - Breast cancer, metastatic

1216 - The importance of primary surgery in patients with de novo stage IV BC survived at least 5- Year; Protocol MF07-01 Randomized Clinical Trial.


29 Sep 2019


Poster Discussion - Breast cancer, metastatic


Vahit Ozmen


Annals of Oncology (2019) 30 (suppl_5): v104-v142. 10.1093/annonc/mdz242


V. Ozmen1, S. Ozbas2, H. Karanlik3, M. Muslumanoglu4, A. Igci4, Z. Canturk5, Z. Utkan5, C. Ozaslan6, T. Evrensel7, C. Uras8, E. Aksaz9, A. Soyder10, U.M. Ugurlu11, C. Col12, N. Cabioglu4, B. Bozkurt6, A. Uzunkoy13, E. Sezgin14, G. Gurleyik15, A. Soran16

Author affiliations

  • 1 Surgery, Istanbul University Istanbul Faculty of Medicine, 34398 - Istanbul/TR
  • 2 Surgery, Guven Hospital, 34538 - Ankara/TR
  • 3 Surgery, Istanbul University Institute of Oncology, 34538 - Istanbul/TR
  • 4 Surgery, Istanbul University Istanbul Faculty of Medicine, 34538 - istanbul/TR
  • 5 Surgery, Kocaeli University Medical School, 34538 - Kocaeli/TR
  • 6 Surgery, Ankara Oncology Hospital, 34538 - Ankara/TR
  • 7 Medical Oncology, Uludag University Medical School, 34538 - Bursa/TR
  • 8 Surgery, Acibadem University, 34538 - istanbul/TR
  • 9 Surgery, MAMER, 34538 - Bursa/TR
  • 10 Surgery, Adnan Menderes University School of Medicine, 34538 - Aydin/TR
  • 11 Surgery, Marmara University Medical School, 34538 - Istanbul/TR
  • 12 Surgery, Izzet Baysal University, 34538 - Bolu/TR
  • 13 Surgery, Harran University, 34538 - SanliUrfa/TR
  • 14 Biostatistics, Ege University, 34538 - İzmir/TR
  • 15 Surgery, Numune Hospital, 34538 - Istanbul/TR
  • 16 Surgery, University of Pittsburgh, 15213 - Pittsburgh/US


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1216


The MF07-01 trial is a multicenter randomized study comparing locoregional treatment (LRT) followed by systemic therapy (ST) with ST alone in de novo stage IV breast cancer (BC) patients. The aim of this study is to evaluate the importance of LRT in patients who lived at least 5 years after the diagnosis of de novo Stage IV BC.


At initial diagnosis, patients were randomized 1:1 to either the LRT or ST group. All the patients were given ST either immediately after randomization or after surgical resection of the intact primary tumor. Continuous and categorical variable differences between LRT and ST groups were analyzed using t-test and Chi-square test, respectively. Overall survival (OS) and 5-year survival rates were compared using Kaplan-Meier log-rank tests. Univariate and multivariate Cox models were used to estimate hazard ratios.


During 124 months of follow-up, 26% of patients in LRT group and 11% of patients in ST group remained alive. Median survival was 46 months for LRT (n = 134) and 35.5 months for ST (n = 132) [HR:0.65, 95%CI;0.49-0.85, p = 0.002]. Solitary bone metastasis patients’ median survival was 14.5 months longer in the LRT group compared with the ST group [HR:0.53, 95%CI; 0.29-0.98, p = 0.04]; 22% of solitary bone metastasis patients in the LRT group and 5% in the ST group were alive. Regarding the patients who lived at least 5 years since randomization, LRT (p = 0.004), hormone receptor positivity (p = 0.007), hormonotherapy (p = 0.0001), bisphosphonates usage (p = 0.02), T2 tumor (p = 0.0008) and 2 or more organ metastases (p = 0.007) were associated with OS in univariate analysis, and in a multivariate Cox proportional model with a significant baseline and clinical characteristics, LRT [OR = 1.75, p = 0.05)], bisphosphonates usage [OR = 1.93, p = 0.05), T2 tumor [OR = 3.5, p = 0.003), and 2 or more organ metastases [OR = 0.48, p = 0.03] were found to be significantly related with OS.


In the current analysis, patients at the diagnosis of de novo stage IV BC who underwent LRT followed by ST had a 75% higher chance to live at least 5 years compared with the patients who received only ST. Longer follow-up of the study discloses that LRT should be presented to the patient when discussing treatment options.

Clinical trial identification


Editorial acknowledgement

Legal entity responsible for the study

Turkish Federation of Breast Diseases Societies.


Turkish Federation of Breast Diseases Societies.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.